Research Article
A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
Table 1
Basic information of the enrolled literature.
| Author | Year | Phase | Patient | Arm 1 | Arm 2 | Patients | Total | PD-L1 negative | PD-L1 positive | Outcomes |
| Bachelot et al. [15] | 2021 | II | TNBC | Durvalumab | Maintenance chemotherapy | 82 | 32 | 29 | OS, PFS, AEs | Brufsky et al. [16] | 2021 | II | mTNBC | Cobimetinib | Placebo + paclitaxel | 62 | 44 | 18 | OS, PFS, AEs | Cortes et al. [17] | 2020 | III | mTNBC | Pembrolizumab | Placebo + chemotherapy | 847 | — | — | PFS, AEs | Emens et al. [18] | 2021 | III | TNBC | Atezolizumab | Placebo + nab-paclitaxel | 902 | 533 | 369 | OS, PFS, AEs | Miles et al.[19] | 2021 | III | mTNBC | Atezolizumab | Placebo + paclitaxel | 651 | 293 | 358 | PFS, OS, AEs | Schmid et al. [20] | 2020 | III | Stage II/III TNBC | Pembrolizumab | Placebo | 1174 | 973 | 196 | PFS, AEs | Winer et al. [21] | 2021 | III | mTNBC | Pembrolizumab | Chemotherapy | 622 | 217 | 405 | OS, PFS, AEs |
|
|
TNBC: triple-negative breast cancer; PD: progression death; OS: overall survival; PFS: progression-free survival; AEs: adverse events.
|